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Abstract
In pediatric sickle cell disease (SCD) patients, it has been reported that higher systolic blood pressure (SBP) is
associated with increased risk of a silent cerebral infarction (SCI). SCI is a major cause of neurologic morbidity in
children with SCD, and blood pressure is a potential modulator of clinical manifestations of SCD; however, the risk
factors underlying these complications are not well characterized. The aim of this study was to identify genetic
variants that influence SBP in an African American population in the setting of SCD, and explore the use of SBP as
an endo-phenotype for SCI. We conducted a genome-wide meta-analysis for SBP using two SCD cohorts, as well as
a candidate screen based on published SBP loci. A total of 1,617 patients were analyzed, and while no SNP reached
genome-wide significance (P-value<5.0x10-8), a number of suggestive candidate loci were identified. The most
significant SNP, rs7952106 (P-value=8.57x10-7), was in the DRD2 locus on chromosome 11. In a gene-based
association analysis, MIR4301 (micro-RNA4301), which resides in an intron of DRD2, was the most significant gene
(P-value=5.2x10-5). Examining 27 of the previously reported SBP associated SNPs, 4 SNPs were nominally
significant. A genetic risk score was constructed to assess the aggregated genetic effect of the published SBP
variants, demonstrating a significant association (P=0.05). In addition, we also assessed whether these variants are
associated with SCI, validating the use of SBP as an endo-phenotype for SCI. Three SNPs were nominally
associated, and only rs2357790 (5’ CACNB2) was significant for both SBP and SCI. None of these SNPs retained
significance after Bonferroni correction. Taken together, our results suggest the importance of DRD2 genetic
variation in the modulation of SBP, and extend the aggregated importance of previously reported SNPs in the
modulation of SBP in an African American cohort, more specifically in children with SCD.
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Introduction
Sickle cell disease (SCD) is an inherited hemoglobin disorder
affecting approximately 1 in 600 individuals of African American
ancestry in the United States [1]. The clinical manifestations of
SCD begin early in life [2] and continue with an increasing
incidence of adverse events, involving genetic as well as
environmental factors [3]. Previous studies have demonstrated
that the arterial blood pressure in steady state patients with
SCD is significantly lower than that of age, sex and race
matched controls [4-9]. These findings are counterintuitive in
view of the well-known vascular and renal abnormalities
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associated with SCD and the high prevalence of hypertension
in African American adults [10-12]. Recently, in SCD children
with no history of overt stroke or seizures, we have reported
that higher systolic blood pressure (SBP) is associated with
increased risk of an silent cerebral infarction (SCI) [13], a
common form of neurological injury among children with SCD,
occurring in at least 27% prior to six years of life and 37% by
14 years of life [14,15]. In addition, previous clinical studies
have shown that the SCD may have a deleterious effect on
myocardium, which contributes to abnormal rates of change in
left ventricular cavity size and systolic/diastolic function in SCD
patients [16-18]. Indeed, nearly one third of adults with SCD
also develop an elevated tricuspid regurgitant velocity (TRV)
that is associated with a much higher death rate in SCD
patients compared to patients with SCD without elevated TRV.
About 5-10% of these patients have true pulmonary
hypertension [19]. Identifying genetic factors associated with
systolic blood pressure (SBP) may help define both patho-
physiological mechanisms, as well as identify patients at
increased risk for SCI.
Studies of familial aggregation provide significant evidence
that blood pressure is a highly heritable trait [20]; however,
these estimates provide no information as to whether the same
genetic variants influence blood pressure across human
populations. In 2009, two genome-wide association studies
(GWAS) and meta-analysis of inter-individual blood pressure
variation in adults were conducted by the Cohorts for Heart and
Aging Research in Genome Epidemiology (CHARGE)
Consortium [21] and the Global Blood Pressure Genetics
(Global BPgen) Consortium [22], leading to the identification of
a number of genomic loci implicated with these traits, including
7 for SBP. Subsequently, these consortia were combined and
expanded to form the International Consortium for Blood
Pressure (ICBP), who reported many additional novel loci for
these traits utilizing individuals of European (N=200,000), East
Asian (N=30,000), South Asian (N=24,000) and African
(N=20,000) descents [23]. In the present study, we sought to
apply two complementary approaches for identifying SBP
variants in individuals with SCD. First, we performed a
genome-wide association study for SBP in SCD cohorts of
African American ancestry. Second, we attempted to validate
the ICBP identified SBP loci in these patients. Finally, we
assessed whether these reported variants are also associated
with SCI, exploring the use of SBP as an endo-phenotype for
SCI.
Methods
Study and Population Samples
This study includes two unrelated admixed African American
ancestry SCD cohorts. Study protocols of both cohorts were
approved by the Institutional Review Board (IRB) of Johns
Hopkins University and Boston Medical Center. Additionally,
IRB approval was acquired from all of the participating sites for
subject enrollment and conducted in accordance with
institutional guidelines.
Silent Infarct Transfusion (SIT) Trial cohort
The Silent Infarct Transfusion (SIT) Trial is an international,
multi-center clinical study funded by the National Institute of
Neurological Disorders and Stroke (NINDS) (http://
sitstudy.wustl.edu/) [24]. All the participants included in our
study are of African American ancestry and written informed
consent was obtained from parents of the SCD-affected
individuals. For each patient, DNA was collected from Epstein-
Barr virus (EBV) transformed lymphoblasts using Puregene
Genomic DNA Purification kits (Gentra Systems, Inc).
Demographic and phenotypic information were collected for
each participant and the inclusion criteria for the recruitment
were age (5-15 years) and hemoglobinopathy diagnosis (either
Hb SS or Hb SB0-thalassemia). Details of the SIT Trial study
design are given elsewhere [24].
Cooperative Study of Sickle Cell Disease
The Cooperative Study of Sickle Cell Disease (CSSCD) was
a multi-institutional prospective longitudinal study of SCD
funded by the National Heart, Lung, and Blood Institute
(NHLBI) of the National Institutes of Health (NIH) [25]. In our
study, we only included CSSCD participants who are of African
American ancestry, and to match the samples with the SIT Trial
cohort, age inclusion criteria of <15 years was used. Details of
the CSSCD study design are given elsewhere [25].
Phenotype Assessment
Systolic Blood Pressure (SBP).  In the SIT Trial, a single
measurement of blood pressure was obtained at well-visit for
children with SCD. No guidelines were formulated to include
uniform assessment. In the CSSCD cohort, longitudinal blood
pressure measurements were collected during routine visits but
not during episodes of acute illness. Blood pressure
measurements were made by study nurses or physicians
following the procedure described in the study manual of
operations [25]. Subjects were asked not to smoke for at least
30 minutes prior to the examination and were allowed to rest
quietly for at least 5 minutes before the measurement was
made. A single measurement of pressure was made with the
patient in the sitting position. Mercury sphygmomanometers
were used for the measurement with a cuff size sufficient to
cover two thirds of the upper arm. Systolic and diastolic
pressures were reported as the first and fifth Korotkoff sounds,
respectively.
Silent Cerebral Infarction (SCI).  A magnetic resonance
imaging (MRI) was obtained from all participants and the
presence or absence of SCI was adjudicated by a blinded
panel of three expert neuro-radiologists.
Genotyping and Quality Control
Genotyping of the SIT Trial cohort was performed in two
stages. For stage 1, a subset of 573 samples, along with 24
International HapMap Consortium [26] controls and 13 known
duplicates, were genotyped at the Center for Inherited Disease
Research (CIDR) at Johns Hopkins University using the
Illumina HumanHap650Y SNP array (Illumina Inc., San Diego
CA, USA). This array contains approximately 661,000 SNPs, of
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which ~100,000 were selected as tags for populations with
African ancestry [27]. The Beadstudio software (Illumina Inc.)
was used to cluster the data and samples with <96.5% call rate
were re-genotyped. The reproducibility, calculated from
duplicate pairs was 99.98% and genotype concordance with
HapMap data was 99.76%. In stage 2, 509 samples were
genotyped at the Center for Disease Control (CDC) at
Washington University using the Illumina Infinium
HumanOmni1-Quad SNP array (Illumina Inc.) and achieved the
call rate of ≥96%.
For quality control (QC), we performed several rounds of
data cleaning and a 96.5% cutoff was used for the sample call
rate and SNP coverage in the combined SIT Trial data
(n=1082), and resulted the exclusion of 6 individuals and 1,260
SNPs from the study. Cryptic relatedness was determined by
examining pair-wise identity-by-descent (IBD), and 77 samples
were identified as first-degree relatives and dropped from the
study. Given the admixed nature of the study participants, we
used principal component analysis (PCA) as implemented in
EIGENSTRAT [28] to both identify genetic outliers (>6 standard
deviations on any of the top ten principal components) and
correct for any potential residual population substructure. In the
SIT Trial, twenty-six individuals were identified as genetic
outliers and further excluded from the analysis. Additionally, 48
samples, due to incomplete phenotype data, were also
dropped from the study, leaving 925 samples (males: 51.9% &
females: 48.1%) for the subsequent GWAS analysis. Among
them, 89% of the samples (n=826/924) had a confirmed SCI
status and 98 individuals (11%) were not classified. In total,
251 SCI positive and 575 SCI negative samples were assigned
as cases and controls, respectively.
In the CSSCD cohort, DNA samples were genotyped at
Boston University using Illumina Human610-Quad SNP arrays
(Illumina, San Diego, CA, USA) with approximately ~600,000
SNPs. All samples were processed according the
manufacturer’s protocol and the BeadStudio software was used
to make genotype calls utilizing the Illumina pre-defined
clusters. Samples with <95% call rate were removed and SNPs
with a call rate <97.5% were re-clustered. After re-clustering,
SNPs with call rates >97.5%, cluster separation score >0.25,
and excess heterozygosity between -0.10 and 0.10 were
retained in the analysis. The pair-wise IBD was used to identify
cryptic relatedness and PCA was applied to detect genetic
outliers. After excluding these samples and following the SIT
Trial age inclusion criteria (<15 years), analysis was restricted
to a dataset of 692 samples (males: 52% & females: 48%).
Merging GWAS Data and Imputation
To infer un-genotyped SNPs and fill-in missing data in the
SIT Trial and CSSCD cohort, HumanHap650Y, HumanOmni1-
Quad and Human610-Quad SNP array datasets were merged
and subsequently imputation was performed for autosomes
using a Hidden Markov model, as implemented in the MaCH
software [29] (version 1.16) (http://www.sph.umich.edu/csg/
abecasis/MaCH/), with 50 rounds and 200 states. QC was
performed both before and after imputation and poorly imputed
SNPs (RSq <0.5, squared correlation between imputed and
true genotypes) were excluded and total 1,019,297 SNPs were
analyzed.
SNP Selection for Validation
Due to the lack of any published studies that report genetic
determinants for SBP in children, and/or more specifically in
African American children at genome-wide significance, we
used the ICBP identified SBP SNPs for validation. To validate
results from the ICBP study in SCD patients, we examined the
28 SNPs that were reported associated with SBP [23]. For
SNPs that were not available on our genotyping array, a close
proxy for the index SNP with criteria of r2 ≥ 0.6 from HapMap
Phase III (release 2, ASW panel) [30] or 1000 Genomes project
(Pilot 1, YRI panel) [31] was used.
GWAS Meta-analysis and Statistics
All quality control measures in both cohorts were performed
using the PLINK software package [32], version 1.06 (http://
pngu.mgh.harvard.edu/purcell/plink/). In the SIT Trial cohort, to
account for the uncertainty of the imputed data, the estimated
allele dosage was analyzed using ProABEL [33] under a
multivariate linear regression framework. Association for each
SNP was assessed after adjusting for age, sex, height and the
1st principal component, and assuming an additive effect of
allele dosage on SBP. In the CSSCD cohort, SBP
measurements were available for longitudinal time points and
data was analyzed using a linear mixed effect model using the
lme4 package (http://lme4.r-forge.r-project.org/) in R (http://
www.r-project.org/) (version 2.14.1). In the mixed effect model,
age, sex, height and the 1st principal component were used as
fixed effect covariates, while multiple SBP measurements
within each individual were treated as random effect. GWAS
results from both the cohorts were meta-analyzed using
inverse-variance weighted fixed-effect models as implemented
in METAL (http://www.sph.umich.edu/csg/abecasis/metal) [34].
The variance inflation factor for genomic control (λGC), as
described by Devlin and Roeder [35], was evaluated in each
cohort prior to meta-analysis and a total of 1,019,297 SNPs
were meta-analyzed. To explore the previously published SBP
associated SNPs [23], a one-sided test of significance was
used. To estimate the effect of these SNPs on SCI (data
available only from the SIT Trial cohort), multivariate logistic
regression was used after adjustments for age, sex and 1st
principal component. The genetic risk scores for SBP and SCI
were constructed (based on previously published SBP variants
and weighted according to their effect sizes) using an R
package Genetics ToolboX (http://cran.r-project.org/web/
packages/gtx/index.html). To construct the genetic risk scores,
this R package uses the same underlying statistics which was
used by the ICBP [23] and can be defined as follows:
Assuming a set of m SNPs from a discovery panel, for the i-th
SNP in the j-th individual denotes xij as the coded genotype (for
directly genotyped SNPs) or estimated allele dosage (in case
of imputation). If the set of regression coefficients of the
reported SNPs are w1, w2. . wm, then the risk score for
individual j is defined as: sj = so + w1 x1j + w2 x2j + … + wm xmj, where
so is the intercept. In our analyses, we specify the coefficient
w1, w2. . wm, to be the effect sizes (in mmHg per coded allele).
Meta-Analysis of Systolic Blood Pressure in SCD
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Further, to identify known functional regulatory variants within
or in proximity to the loci of interest, the GTEx (Genotype-
Tissue Expression) expression quantitative trait loci (eQTL)
database was queried (http://www.ncbi.nlm.nih.gov/gtex/
GTEX2/gtex.cgi) [36].
Gene-based Association Testing
To increase power by combining independent associations
within a gene into a single, stronger aggregated signal, gene-
based association tests were performed using GWiS [37].
GWiS uses greedy Bayesian model selection (selecting a
minimal subset of associated SNPs within a gene) to identify
independent effects and estimates overall significance through
permutation. For each test statistics, using meta-analysis
summary data, the gene P-values were computed using
1,000,000 permutations and utilizing the 1000 Genomes
Project ASW panel as a reference population to account for
linkage disequilibrium (LD) between SNPs.
Results
Genome-wide single SNP association
Genome-wide association and meta-analysis was performed
for SBP in 1,617 subjects (843 males, 774 females) from the
SIT Trial and CSSCD cohorts. The average ages of studied
samples from the SIT Trial and CSSCD cohorts were 8.96 and
9.57 years, respectively. Detailed demographic and clinical
characteristics for the study subjects are described in Table 1.
The observed P-values show no early departure from the null
(Figure S1), indicating minimal inflation (λGC=0.998) in test
statistics due to potential population stratification and/or cryptic
relatedness. None of the SNPs reached genome-wide
significance (P-value <5.0x10-8) (Figure 1). However, a number
of suggestive candidate loci (P-value <5.0x10-5) were identified
that approached genome-wide significance (Table 2). The most
significant signal was observed for rs7952106 (P-value: SIT
Trial=6.40x10-3; CSSCD=3.94x10-5; Meta-analysis=8.57x10-7).
This SNP is located ~78 kb 5’ upstream of the dopamine
receptor D2 subtype (DRD2) gene on chromosome 11.
rs7952106 is a common SNP with a minor allele frequency
(MAF) of 23%, and directly genotyped in both the cohorts. The
direction effect of the minor allele (G) is consistent across both
GWAS (SIT Trial: Effect size=1.65 mmHg/allele; CSSCD:
Effect size=1.50 mmHg/allele) and associated with increase in
SBP. A second DRD2 intronic SNP (rs17529477; minor allele
frequency [A] =12%) showed the same direction effect (Effect
size=1.76 mmHg/minor allele; P-value=1.93x10-5) and was in
low LD with rs7952106 (r2: SIT Trial=0.25 and CSSCD=0.24).
Gene-based association analysis
Given the suggestion of multiple independent signals in
DRD2, we performed a gene-based test combining
independent associations within a gene (using 20kb flanking
region) and obtained a P-value for each gene using
permutation. In total, 32,155 autosomal genes were tested, and
results are shown in Table 3. Among all the tested genes, none
met the genome-wide significant criteria (P-value < 2.0x10-6).
The most significant gene was MIR4301 (micro-RNA4301,
Gene ID: 100422855) with a P-value=5.2x10-5 (Table 3).
MIR4301 is a 65 base-pair long non-coding RNA at
chromosome 11 and contained within the DRD2 intronic region,
and shares the same set of associated SNPs as observed for
the DRD2 gene. To examine micro-RNA target binding
predictions, we used the software RNA22 (version 1.0) (http://
cbcsrv.watson.ibm.com/rna22.html) [38]. MIR4301 showed a
predicted target site in the 3’ UTR region of the DRD2
transcript (ENSEMBL: ENST00000355319). In our study, the
observed suggestive genetic signals of DRD2 region SNPs and
the prediction of MIR4301 binding to DRD2 as a potential
target, suggests the plausible involvement of DRD2 region in
the regulation of SBP in SCD cohorts. Examining the GTEx
database, which queries lymphoblastoid, liver, brain
cerebellum, frontal cortex, and temporal cortex tissue, we
found no known eQTLs within or in close proximity of this
locus.
Association of previously reported SBP loci
A total of 29 independent chromosomal loci associated with
blood pressure have been reported from the ICBP meta-
analysis, of which 28 show strong evidence for association with
SBP. We attempted to validate these loci in the combined SCD
cohorts. To ensure uniform comparison of the genetic effect
and its direction, the SNPs were analyzed according to the
reported coded alleles (under an additive genetic model). We
were able to test 27 of these SNPs directly or with a proxy SNP
(r2≥0.6), and 15/27 SNPs showed the same direction affect on
SBP as reported in the ICBP study (Table 4, Figure S2). Of the
directly genotyped/imputed or proxy SNPs, 4 were nominally
significant in the combined SCD cohorts, and 6 were significant
at P-value <0.10 (Table 4), demonstrating a clear enrichment of
signal (P-value =0.0045). However, none of the 27 tested
SNPs was significant after Bonferroni correction
Table 1. Demographic and clinical characteristics of the SIT
Trial and CSSCD cohorts.
Variables SIT Trial CSSCD P-value*
Sex, n (%)    
Men 483 (52.2%) 360 (52%) 0.89
Age (in years), mean ± SD 8.96 ± 2.44 9.57 ± 2.91 0.002
Baseline SBP† (mm Hg), mean ± SD 108.2 ± 11.51 100.8 ± 10.99 <0.001
Baseline DBP‡ (mm Hg), mean ± SD 60.58 ± 8.06 59.21 ± 10.27 0.04
Height (cm), mean ± SD 128.70 ± 14.37 131.5 ± 16.08 0.008
Hemoglobin (g/dl), mean ± SD 8.11 ± 1.08 8.13 ± 0.96 0.41
Hematocrit (%), mean ± SD 23.34 ± 3.42 23.57 ± 3.10 0.12
White blood counts (Cu), mean ± SD 12.58 ± 5.25 12.01 ± 2.56 0.13
Fetal hemoglobin (%), mean ± SD 8.93 ± 5.75 8.00 ± 7.45 0.014
The shown laboratory assessments for both the cohorts are at baseline
*. P-values for continuous and categorical variable comparisons were generated
using wilcoxon rank sum and Kruskal-Wallis test, respectively
†. SBP indicates systolic blood pressure
‡. DBP indicates diastolic blood pressure
doi: 10.1371/journal.pone.0074193.t001
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(α=0.05/27=1.85x10-3). Given the limited power to detect
significance for individual SNPs in the relatively smaller SCD
samples (Figure S3), we constructed a genetic risk score for
SBP incorporating the 27 previously reported SNPs; weighted
according to effect sizes observed in the ICBP meta-analysis.
The risk score derived from these 27 directly genotyped or
proxy SNPs was nominally associated with SBP (P-value=
0.05), demonstrating the role of these SNPs in aggregate in the
modulation of SBP in the SCD cohort.
Association of SBP reported loci with SCI
Given that higher SBP is associated with increased risk of an
SCI in SCD patients, we determined whether any of the SNPs
(or their proxies) associated with SBP in ICBP study was
associated with SCI. Three SNPs were nominally associated
with SCI (Table 4), with only the CACNB2 (5’) locus
(rs2357790) consistent between the SBP (P-value=0.05) and
SCI (P-value=0.04) analyses. None of these SNPs was
significant after Bonferroni correction. Further, to estimate the
aggregated effect of these SNPs on increased risk of SCI, we
constructed the genetic risk score for SCI (weighted according
to effect sizes of published SBP SNPs) and no significant
association was observed (P-value= 0.95).
Discussion
In recent years, genome-wide scans demonstrated a
successful means of identifying novel common genetic variants
that contribute to susceptibility to complex diseases, including
blood pressure [21-23,39,40]. Here, we present the results
from a meta-analysis of SBP from two SCD cohorts comprised
of 1,617 SCD patients, all with African American ancestry. No
associations were genome-wide significant; however we
observed suggestive association at rs7952106, a 5’ upstream
SNP to DRD2 gene on chromosome 11, which showed
consistent association evidence in both the studied cohorts.
Further, in a gene-based test, a suggestive signal of non-
coding RNA (MIR4301) and the prediction of MIR4301 binding
to DRD2 as a potential target, suggests the plausible
involvement of DRD2 region in the regulation of SBP in SCD
cohorts.
Previously, several studies have shown that dopamine
synthesis in the kidney has an important role in the regulation
of fluid and electrolyte balance and systemic blood pressure
[41-43]. Dopamine exerts its actions via 2 families of G-protein-
coupled receptors D1-like receptors (DRD1 and DRD5) and
D2-like receptors (DRD2, DRD3, and DRD4). Later, several
lines of evidence also showed that an intact dopaminergic
system is necessary to maintain normal blood pressure and
that genetic hypertension is associated with alterations in
dopamine production and receptor function [41-44]. Deletion of
any dopamine receptor in mice results in increased blood
pressure by mechanisms that are receptor dependent. In
particular, mice lacking the DRD2 gene (DRD2-/-
) have reactive oxygen species (ROS)-dependent
hypertension [44]. In addition, the DRD2 polymorphisms were
also reported with decreased DRD2 expression [45] and shown
to affect DRD2 mRNA stability and synthesis of the receptor
[46]. These studies suggest that the DRD2 locus is plausibly
involved in the regulation of SBP. Our results support these
findings and the suggestive association from the DRD2 region
SNPs may represents a true signal associated with SBP in
SCD patients.
Figure 1.  Manhattan plot showing the association of SNPs with systolic blood pressure (SBP).  The genome-wide
distribution of -log10 P-values are plotted against the physical position of each SNP on each chromosome. The threshold for
genome-wide significance (P-value < 5.0x10-8) is indicated by the horizontal dashed line.
doi: 10.1371/journal.pone.0074193.g001
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Table 2. Association summary of top scoring independent loci of systolic blood pressure GWAS.
Chr SNP Position Nearest GeneLocation
CA/
OA CAF RSq*
SIT Trial† (n=925, age
<15 yrs)  
CSSCD‡ (n=692, age <15
yrs)  Meta-analysis














0.3 0.76 0.61 0.78 0.43  1.71 0.35 1.08x10-6  1.52 0.32 2.0x10-6 ++





0.17 1 -0.81 0.68 0.23  -1.95 0.41 2.41x10-6  -1.64 0.35 3.54x10-6 −
3 rs17586876 2,939,182 CNTN4 Intron
A/
G
0.92 0.92 0.58 1.13 0.61  -2.95 0.58 3.02x10-7  -2.22 0.51 1.56x10-5 +-
3 rs826221 24,243,440 THRB Intron
A/
G
0.93 0.87 -1.9 1.03 0.06  -3.03 0.72 2.61x10-5  -2.66 0.59 6.96x10-6 −
4 rs10520528 183,497,595 ODZ3 Intron
T/
G







0.23 0.63 -2.43 0.68 0.0004  -1.51 0.56 0.0066  -1.88 0.43 1.30x10-5 −
6 rs4869931 151,051,582 PLEKHG1 Intron
A/
G
0.47 0.97 0.12 0.53 0.81  1.61 0.32 3.90x10-7  1.21 0.27 8.48x10-6 ++
8 rs1442407 3,078,991 CSMD1 Intron
T/
G







0.76 0.76 -2.18 0.6 0.0003  -1.43 0.52 0.0056  -1.75 0.39 8.13x10-6 −
11 rs17529477 112,822,277 DRD2 Intron
A/
G







0.23 1 1.65 0.61 0.0064  1.5 0.36 3.94x10-5  1.54 0.31 8.57x10-7 ++
12 rs11053548 10,061,994 CLEC12B Intron
A/
G
0.91 1 2.77 0.92 0.0022  1.88 0.54 0.00049  2.12 0.46 5.19x10-6 ++
12 rs1989584 62,619,479 SRGAP1 Intron
T/
G
0.36 1 -1.14 0.53 0.034  -1.27 0.33 9.68x10-5  -1.23 0.28 9.64x10-6 −
12 rs11064853 118,544,491 LOC387890 Intron
A/
G







0.1 1 2.37 0.86 0.0063  1.82 0.53 0.00056  1.97 0.45 1.24x10-5 ++
16 rs289673 12,338,371 SNX29 Intron
A/
G
0.67 0.68 -1.63 0.61 0.0077  -1.53 0.45 0.00073  -1.57 0.36 1.75x10-5 −
16 rs7499397 82,177,970 CDH13 Intron
T/
C
0.38 0.92 -1.8 0.57 0.0017  -1 0.32 0.0017  -1.19 0.28 1.98x10-5 −
18 rs1543073 34,149,356 CELF4 5' Upstream
A/
G
0.41 0.93 -0.52 0.56 0.36  -1.44 0.32 7.97x10-6  -1.21 0.28 1.57x10-5 −
21 rs2210268 40,685,128 DSCAM Intron
T/
G
0.83 1 -1.8 0.66 0.0062  -1.43 0.41 0.00049  -1.54 0.35 1.08x10-5 −
Chr: chromosome; CA: coded allele; OA: other allele; CAF: coded allele frequency; RSq: Imputation quality (squared correlation between imputed and true genotypes)
Genomic positions are in reference to NCBI build 36.3
Table includes SNPs with independent effects and whose significance in the meta-analysis is <5.0x10-5.
*. Directly genotyped SNPs are marked as 1
†. Effect size is based on multivariate linear regression (adjusted for age, sex, height and 1st principal component)
‡. Effect size is based on linear mixed model (age, sex, height, 1st principal component and the index SNP were treated as fixed effect covariates and longitudinal
measurements of systolic blood pressure of each individual was used as a random effect)
§. Effect size is based on inverse-variance weighted fixed-effect meta-analysis
The effect size estimates corresponds to mmHg per coded allele for SBP
doi: 10.1371/journal.pone.0074193.t002
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Recently, several large and well powered studies from
European ancestry populations have identified 29 genomic loci
associated with blood pressure [21-23]. We sought to validate
these reported loci in the setting of SCD in populations of
African American ancestry, and to further test whether any of
these loci were involved in SCI. Our study reports that the
derived genetic risk scores for SBP is significantly associated
with SCD children of African American ancestry. The significant
association of the aggregated genetic risk scores with SBP in
our study highlights the importance of these loci in the
modulation of SBP in the studied SCD cohort.
In SCD patients, neurovascular complications are common
and largely due to tissue ischemia and infarctions [13,47]. SCI
Table 3. Gene-based association analysis of systolic blood
pressure.
Chr Gene SNPs† Tests‡ K§ P-value*
 Name Start End     
1 LOC400750 39,154,602 39,196,561 13 6.31 1 0.0011
2 ABCB11 169,759,449 169,907,833 172 22.99 1 3.9x10-4
4 MRFAP1 6,622,445 6,664,449 14 7.59 1 7.4x10-4
5 MIR583 95,394,842 95,434,916 14 4.77 1 1.5x10-4
6 LOC134997 24,956,605 24,997,415 29 7.30 1 7.1x10-4
6 SPATS1 44,290,397 44,364,904 38 11.54 1 4.1x10-4
6 PLEKHG1 150,940,999 151,184,799 141 29.94 1 0.0011
8 LOC100507422 48,484,706 48,525,170 3 2.95 1 9.0x10-4
9 CARM1P1 2,923,562 3,073,404 89 17.04 1 3.1x10-4
10 NUDT13 74,850,210 74,911,581 10 4.55 1 3.1x10-4
10 USP54 75,237,296 75,355,433 10 3.59 1 2.6x10-4
11 OR5D15P 55,534,441 55,575,382 13 7.34 1 0.001
11 OR5W1P 55,650,819 55,691,621 31 8.51 2 3.3x10-4
11 DRD2 113,260,317 113,366,001 61 14.46 2 0.0011
11 MIR4301 113,300,745 113,340,810 17 7.13 2 5.2x10-5
12 CLEC1B 10,125,660 10,171,899 49 9.47 1 2.0x10-4
12 PRKAG1 49,376,055 49,432,629 10 3.69 1 2.9x10-4
12 SRGAP1 64,218,541 64,561,613 101 25.84 1 9.3x10-4
12 TMEM233 120,011,264 120,099,363 24 8.01 2 1.4x10-4
13 KCTD12 77,434,304 77,480,540 23 10.78 1 6.7x10-4
15 BLM 91,240,579 91,378,686 41 11.18 1 9.5x10-4
19 MIR4746 4,425,975 4,466,045 13 2.70 1 0.0010
20 CYB5AP4 22,846,128 22,886,676 13 6.16 1 6.9x10-4
21 DSCAM-AS1 41,735,010 41,777,285 23 9.36 1 1.8x10-4
Gene start and end positions includes ±20 Kb of 5' and 3'-untranslated regions of
the genes.
The threshold for genome-wide gene significance (2.0x10-6) was established using
permutation.
†. Number of SNPs tested in the gene
‡. Effective number of SNPs in the gene
§. Number of SNPs in the model
Significance for the gene model
doi: 10.1371/journal.pone.0074193.t003
is a major cause of neurologic morbidity in SCD children with
unclear genetic susceptibility [47,48]. Given that hypertension
is a known risk factor for stroke and more recently, SBP has
been reported associated with risk for SCI [13,49], identifying
genetic variants associated with SBP in SCD patients may also
lead to the identification of genes associated with SCI.
Although we confirm the association of 4 loci with SBP, only
the CACNB2 (5’) locus showed the consistent nominal
significance for both SBP and SCI (Table 4).
A few limitations to the current study need to be
acknowledged. First, although we observed a significant
association of the aggregated genetic risk score with SBP, we
failed to reproduce the significance of any individual SBP
associated SNPs after multi-test correction and this may be
due to the limited sample size of our study. As shown in Figure
S3, our study (n=1,617) was also under-powered to identify
novel genome-wide significant variants. Secondly, biological
differences that exist between ethnic groups and complex
interaction of age with different genetic alteration may also
have negatively impacted our ability to identify significant loci.
Also, the admixed nature of the African ancestry population
may lead to differences in local LD patterns. Since we are not
likely to be genotyping the functional variant, changes in LD
patterns between Europeans and the studied African American
populations can change the nature of the observed
associations. Thirdly, the ability to detect genetic determinants
associated with any trait of interest largely depends on the
quality and reliability of the data. In our study, it is noteworthy
to highlight that we have used the longitudinal SBP
measurements from the CSSCD cohort, as oppose to the
single time point data available from the SIT Trial. In addition,
CSSCD SBP measurements were taken after following the
procedure described in the study manual of operations, and
hence provides more certainty of less variability, whereas, no
uniform guidelines were adopted in the SIT Trial. At last, it has
also been known for over a decade that blood pressure is an
age-dependent process [50,51]. The ICBP study was
performed in adult individuals (38-72 yrs), whereas in our
study, SCD patients are restricted to age < 15 years; therefore,
it is possible that the lack of association for other loci may be
due to an age-dependent genetic effect.
In summary, our results not only suggest the importance of
DRD2 genetic variation in the modulation of SBP, but also
extend the genetic significance of the 4 previously published
loci in SBP in an African American population. Further, our
study also identifies a significant association for the genetic risk
score with SBP, suggesting the aggregated importance of
previously reported SNPs in the modulation of SBP in the
setting of SCD. This study provides new insight in SBP
regulation in an admixed African American ancestry cohort,
more specifically in children with SCD, and highlights the
overlap in genetic signals between African American
populations and European ancestry populations.
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Table 4. Association of previously reported SBP-associated SNPs with SBP and SCI.






Systolic Blood Pressure (SIT Trial +
CSSCD cohort) (n=1,617)  
Silent Cerebral Infarction
(SIT Trial cohort) (n=826)










































































































































A/G 0.27 Decreases 0.05  0.92 (0.66-1.27) 0.59
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Table 4 (continued).






Systolic Blood Pressure (SIT Trial +
CSSCD cohort) (n=1,617)  
Silent Cerebral Infarction
(SIT Trial cohort) (n=826)










































































A/G 0.22 Increases 0.06  1.22 (0.89-1.69) 0.22
Genomic positions are in reference to NCBI build 36.3
Chr: chromosome; CA: coded allele; OA: other allele; CAF: coded allele frequency; OR: odds ratio; CI: confidence interval
In the absence of the genotype data for the reported index SNP, best proxy was selected using HapMap phase III (release 2, ASW panel) and 1000 Genomes project (Pilot
1, YRI panel ) with cutoff r2 ≥ 0.6
†. Observed effects are based on inverse variance weighted meta-analysis*P-values are based on one-tailed significanceNA indicates opposite direction of effect between
ICBP and SCD cohorts
‡. Odds ratio based on the multivariate logistic regression adjusted for age, sex and 1st principal component
doi: 10.1371/journal.pone.0074193.t004
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Supporting Information
Figure S1.  A quantile-quantile (Q-Q) plot showing the
distribution of observed χ2 statistics of analyzed SNPs in
1,617 SCD individuals (SIT Trial, n=925; CSSCD, n=692).
The black diagonal line indicates expected results under the
null hypothesis.
(TIFF)
Figure S2.  Comparison of the effect size of variants from
the reported regions associated with SBP in the ICBP
meta-analysis and SCD cohort.
(TIFF)
Figure S3.  Power calculation to detect genome-wide
significant SNPs (minor allele frequency > 0.05) for
systolic blood pressure in the combined SIT Trial and
CSSCD cohort, utilizing 1617 SCD samples. The authors
thank the staff, clinicians and patients for their participation in
the Silent Infarct Transfusion (SIT) Trial study. Genotyping
services for the SIT Trial were provided by the Center for
Inherited Disease Research (CIDR) at Johns Hopkins
University and the Division of Blood Disorders at the Centers
for Disease Control and Prevention (CDC). The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for
Disease Control and Prevention.
(TIFF)
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